Brexafemme-Ibrexafungerp
Vulvovaginal candidiasis has been treated with azole antifungals for decades, and resistance plus non-albicans species have eroded their reliability. Brexafemme (ibrexafungerp) introduced the first oral alternative outside that class. Ibrexafungerp is a triterpenoid that inhibits fungal glucan synthase, disrupting cell wall synthesis through a target the azoles do not touch. Taken as a single-day, two-dose […]
Lybalvi-Olanzapine And Samidorphan
Olanzapine is among the most effective antipsychotics available and among the most likely to cause substantial weight gain, a trade-off that limits its use. Lybalvi (olanzapine and samidorphan) attempts to split the difference. Samidorphan, an opioid receptor antagonist, is included specifically to mitigate olanzapine-associated weight gain rather than to treat the psychiatric illness itself. The […]
Truseltiq-Infigratinib
FGFR2 fusions define a targetable subset of cholangiocarcinoma, and several inhibitors reached the market in quick succession. Truseltiq (infigratinib) was the one that did not survive commercially. Infigratinib was an oral FGFR inhibitor blocking the growth signaling that drives these bile duct tumors. Its accelerated approval covered previously treated, unresectable locally advanced or metastatic cholangiocarcinoma […]
Lumakras-Sotorasib
Lumakras (sotorasib) broke a barrier that had stood for nearly four decades, arriving as the first KRAS inhibitor ever approved for a target long considered undruggable. Sotorasib binds irreversibly to a pocket present only in the mutant protein, locking KRAS G12C in its inactive state. The once-daily tablet treats adults with KRAS G12C-mutated locally advanced […]
Pylarify-Piflufolastat F 18
Accurately staging prostate cancer changes treatment decisions, and conventional imaging often misses small metastatic deposits. Pylarify (piflufolastat F 18) brought PSMA-targeted PET into wider practice. It binds PSMA, which is heavily overexpressed on prostate cancer cells, making suspected metastasis or biochemical recurrence visible on PET imaging. The intravenous fluorine-18 agent is approved to identify prostate-specific […]
Empaveli-Pegcetacoplan
Empaveli (pegcetacoplan) moved complement inhibition upstream to C3, addressing the extravascular hemolysis that leaves many paroxysmal nocturnal hemoglobinuria patients anemic despite C5 blockade. By blocking complement at C3 rather than C5, Empaveli controls red cell destruction both inside and outside the blood vessels, addressing the extravascular hemolysis that leaves many patients anemic. It is delivered […]
Nextstellis-Drospirenone And Estetrol
Nextstellis (drospirenone and estetrol) introduced a genuinely new estrogen into a category that had relied on the same one for decades. It is the first birth control pill to use estetrol, an estrogen naturally produced during pregnancy and manufactured here from a plant source, paired with the progestin drospirenone. The combined tablet is taken once […]
Qelbree-Viloxazine
Not every patient with ADHD can or should take a stimulant, and the non-stimulant options had been limited for years. Qelbree (viloxazine) broadened that shortlist. Viloxazine is a selective norepinephrine reuptake inhibitor that improves attention and impulse control without the controlled-substance status or abuse potential of stimulants. The once-daily extended-release capsule is approved for ADHD […]
Zegalogue-Dasiglucagon
Severe hypoglycemia is an emergency, and older glucagon rescue kits required mixing a powder under extreme time pressure. Zegalogue (dasiglucagon) removed that step with a stable, ready-to-use formulation. Supplied as an autoinjector or prefilled syringe requiring no reconstitution, Zegalogue raises blood glucose by prompting the liver to release stored glucose, acting within minutes of injection. […]
Ponvory-Ponesimod
Oral therapies reshaped multiple sclerosis care, and the S1P receptor modulator class has progressively narrowed its targeting to reduce off-target effects. Ponvory (ponesimod) is among the most selective. As a selective sphingosine 1-phosphate receptor 1 modulator, Ponvory sequesters lymphocytes in lymph nodes, reducing immune attacks on myelin. The once-daily tablet covers relapsing forms of multiple […]
